Clinical Trials Browser

Phase 2 × Carcinoma, Non-Small-Cell Lung × Fulvestrant × Clear all

Carcinoma, Non-Small-Cell Lung

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00100854 2019-03-05

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

108 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00932152 2017-10-19

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

3 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00592007 2017-06-06

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Phase 2 Terminated

7 enrolled 3 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

KAT6

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

SUMMIT

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer